8-K Announcements
6Material company update
Apr 29, 2026·SEC
Material company update
Mar 23, 2026·SEC
Material company update
Mar 12, 2026·SEC
Crescent Biopharma, Inc.(CBIO)Earnings, Financials & Key Ratios
CBIO•NASDAQ
$18.26
Price updated Jun 27, 2026
AboutCrescent Biopharma, Inc., an oncology company, develops therapies for cancer patients. Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors. The company is headquartered in Waltham, Massachusetts.Show more
- Revenue$11M
- EBITDA-$153M-205.9%
- Net Income-$154M-217.3%
- EPS (Diluted)-12.81-815.0%
- Gross Margin100%
- EBITDA Margin-1406.75%
- Operating Margin-1407.52%
- Net Margin-1419.61%
- ROE-164.18%+61.2%
CBIO Price & Volume
Crescent Biopharma, Inc. (CBIO) stock price & volume — 10-year historical chart
Loading chart...
Milestone Dependence Masks Persistent Clinical Development Burn
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Healthy
Cash Flow:Burning
Primary Risk:Clinical trial execution failure
"Crescent Biopharma operates as a pre-commercial entity where value is tethered to the successful advancement of its bispecific antibody and ADC pipeline rather than recurring revenue. While the firm maintains a substantial $189.2 million cash position to fund its high-intensity R&D operations, the lack of sustainable commercial sales and a $195.1 million cumulative deficit in retained earnings present significant long-term solvency risks. Investors should monitor the firm's ability to achieve clinical milestones, as the current reliance on episodic licensing inflows may necessitate further dilutive capital raises to sustain the $95.0 million quarterly R&D expenditure observed in 2025Q4."
Verdict Logic
the firm's reliance on sporadic milestone payments to offset a $95.0 million quarterly R&D burn rate creates excessive clinical execution risk for long-term investors.
CBIO Growth Metrics
Crescent Biopharma, Inc. (CBIO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-5.97%
5 Years1.31%
3 Years424.86%
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-206.18%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-442.79%
Return on Capital
10 Years-74.67%
5 Years-103.8%
3 Years-127.95%
Last Year-132.59%
CBIO Recent Earnings
Crescent Biopharma, Inc. (CBIO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 2/12 qtrs (100%)
Q2 2026Latest
Apr 29, 2026Metric
Actual
Est
EPS
$0.70+17.6%
$0.85
Rev
$1M+180.0%
$357,143
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$4.01-80.6%
$2.22
Rev
$11M+8.4%
$10M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$1.27-25.7%
$1.01
Rev
—
—
Q3 2025
Jul 31, 2025Metric
Actual
Est
EPS
$4.93-83.3%
$2.69
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 29, 2026 | $0.70vs $0.85+17.6% | $1Mvs $357,143+180.0% |
| Q1 2026 | Feb 26, 2026 | $4.01vs $2.22-80.6% | $11Mvs $10M+8.4% |
| Q4 2025 | Nov 6, 2025 | $1.27vs $1.01-25.7% | — |
| Q3 2025 | Jul 31, 2025 | $4.93vs $2.69-83.3% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Crescent Biopharma, Inc. (CBIO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $18.26 | $503.46M | -1.43 | — | -1419.61% | -164.18% | — | |
| $31.00 | $3.12B | -9.42 | -4.26% | -156.36% | -68.97% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $108.12 | $8.83B | -29.30 | -16.72% | -612.17% | -25.02% | — | |
| $1.08 | $4.8M | -0.17 | — | — | -729.89% | — | |
| $3.03 | $126.18M | -891.18 | 10.37% | 52.16% | — | — |
Compare CBIO vs Peers
Crescent Biopharma, Inc. (CBIO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CBIO SEC Filings & Documents
Crescent Biopharma, Inc. (CBIO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when CBIO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CBIO Frequently Asked Questions
Crescent Biopharma, Inc. (CBIO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Crescent Biopharma, Inc.'s revenue?
Crescent Biopharma, Inc. (CBIO) reported $11.9M in revenue for fiscal year 2025. This represents a 212% increase from $3.8M in 2011.
Is CBIO profitable?
Crescent Biopharma, Inc. (CBIO) reported a net loss of $162.1M for fiscal year 2025.
Dividend & Returns
What is CBIO's return on equity?
Crescent Biopharma, Inc. (CBIO) has a return on equity (ROE) of -164.2%. Negative ROE indicates the company is unprofitable.
What is Crescent Biopharma, Inc.'s free cash flow?
Crescent Biopharma, Inc. (CBIO) had negative free cash flow of $27.4M in fiscal year 2025, likely due to heavy capital investments.